Alexander Gintsburg, director of the Gamaleya Center for Epidemiology and Microbiology Research, said that trials of a monoclonal vaccine against coronavirus on volunteers will begin next week. DEA Novosti.
On April 18, the first volunteers delivered the drug to St. At the Influenza Research Institute of the Ministry of Health in St. Petersburg, all documents have already been signed. Gunzburg added that in the second phase, the drug will be tested on coronavirus patients. Based on the results of this phase, the Ministry of Health plans to address the issue of vaccine registration.
clinical trials of the vaccine started In January. Prior to this, the Gamaleya Center reported that this drug was effective against the “omicron” strain. The drug is administered intravenously using a dropper. The drug neutralizes the virus, and after a week the patient develops his own antibodies. Conventional antibodies are rapidly excreted from the body by the kidneys, while monoclonal antibodies can circulate in the blood for more than ten days.